Lundbeck has gained orphan drug designation (ODD) from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of ...

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

If you want to read more about the recent tariffs imposed by the US you can look at the 10 Most Undervalued High Quality ...

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease ...

Afflicting an estimated four in 100,000 people, Multiple System Atrophy (MSA) causes gradual damage to nerve cells in the brain, affecting movement, balance and basic functions like breathing ...

Phase 2 trial shows promising results in slowing disease progression Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has reported positive Phase 2 trial results for ATH434, its lead candidate for ...

The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...